[go: up one dir, main page]

WO2009059972A3 - Biochemical markers for cvd risk assessment - Google Patents

Biochemical markers for cvd risk assessment Download PDF

Info

Publication number
WO2009059972A3
WO2009059972A3 PCT/EP2008/064946 EP2008064946W WO2009059972A3 WO 2009059972 A3 WO2009059972 A3 WO 2009059972A3 EP 2008064946 W EP2008064946 W EP 2008064946W WO 2009059972 A3 WO2009059972 A3 WO 2009059972A3
Authority
WO
WIPO (PCT)
Prior art keywords
risk assessment
biochemical markers
neo
cvd risk
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/064946
Other languages
French (fr)
Other versions
WO2009059972A2 (en
Inventor
Morten Karsdal
Per Qvist
Natasha Barascuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nordic Bioscience AS
Original Assignee
Nordic Bioscience AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721713A external-priority patent/GB0721713D0/en
Priority claimed from GB0722748A external-priority patent/GB0722748D0/en
Priority claimed from GB0802814A external-priority patent/GB0802814D0/en
Priority to CN2008801239120A priority Critical patent/CN101918846A/en
Application filed by Nordic Bioscience AS filed Critical Nordic Bioscience AS
Priority to US12/740,648 priority patent/US9359633B2/en
Priority to EP08847014.1A priority patent/EP2208073B1/en
Priority to EP12185053.1A priority patent/EP2538222B1/en
Priority to DK08847014.1T priority patent/DK2208073T3/en
Priority to ES08847014T priority patent/ES2777948T3/en
Priority to JP2010532571A priority patent/JP6039879B2/en
Publication of WO2009059972A2 publication Critical patent/WO2009059972A2/en
Publication of WO2009059972A3 publication Critical patent/WO2009059972A3/en
Priority to US12/749,652 priority patent/US9206464B2/en
Anticipated expiration legal-status Critical
Priority to US13/187,205 priority patent/US9404932B2/en
Priority to US14/960,713 priority patent/US9606130B2/en
Priority to US15/173,852 priority patent/US10267809B2/en
Priority to US15/446,070 priority patent/US9880177B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.
PCT/EP2008/064946 2007-11-05 2008-11-04 Biochemical markers for cvd risk assessment Ceased WO2009059972A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DK08847014.1T DK2208073T3 (en) 2007-11-05 2008-11-04 BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT
ES08847014T ES2777948T3 (en) 2007-11-05 2008-11-04 Biochemical markers for CVD risk assessment
JP2010532571A JP6039879B2 (en) 2007-11-05 2008-11-04 Biochemical markers for CVD risk assessment
EP12185053.1A EP2538222B1 (en) 2007-11-05 2008-11-04 Biochemical markers for CVD risk assessment
CN2008801239120A CN101918846A (en) 2007-11-05 2008-11-04 Biochemical markers for CVD risk assessment
US12/740,648 US9359633B2 (en) 2007-11-05 2008-11-04 Biochemical markers for CVD risk assessment
EP08847014.1A EP2208073B1 (en) 2007-11-05 2008-11-04 Biochemical markers for cvd risk assessment
US12/749,652 US9206464B2 (en) 2007-11-05 2010-03-30 Fibrosis biomarker assay
US13/187,205 US9404932B2 (en) 2007-11-05 2011-07-20 Pathology biomarker assay
US14/960,713 US9606130B2 (en) 2007-11-05 2015-12-07 Fibrosis biomarker assay
US15/173,852 US10267809B2 (en) 2007-11-05 2016-06-06 Biochemical markers for CVD risk assessment
US15/446,070 US9880177B2 (en) 2007-11-05 2017-03-01 Fibrosis biomarker assay

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0721713.6 2007-11-05
GB0721713A GB0721713D0 (en) 2007-11-05 2007-11-05 Biochemical markers of cvd risk
GB0722748A GB0722748D0 (en) 2007-11-20 2007-11-20 Biochemical markers of CVD risk
GB0722748.1 2007-11-20
GB0802814A GB0802814D0 (en) 2008-02-15 2008-02-15 Biochemical markers of CVD risk assessment
GB0802814.4 2008-02-15

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/740,648 A-371-Of-International US9359633B2 (en) 2007-11-05 2008-11-04 Biochemical markers for CVD risk assessment
US12/749,652 Continuation-In-Part US9206464B2 (en) 2007-11-05 2010-03-30 Fibrosis biomarker assay
US15/173,852 Continuation US10267809B2 (en) 2007-11-05 2016-06-06 Biochemical markers for CVD risk assessment

Publications (2)

Publication Number Publication Date
WO2009059972A2 WO2009059972A2 (en) 2009-05-14
WO2009059972A3 true WO2009059972A3 (en) 2009-09-17

Family

ID=40325741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/064946 Ceased WO2009059972A2 (en) 2007-11-05 2008-11-04 Biochemical markers for cvd risk assessment

Country Status (7)

Country Link
US (2) US9359633B2 (en)
EP (5) EP2538222B1 (en)
JP (3) JP6039879B2 (en)
CN (3) CN101918846A (en)
DK (2) DK2208073T3 (en)
ES (2) ES2897492T3 (en)
WO (1) WO2009059972A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206464B2 (en) 2007-11-05 2015-12-08 Nordic Bioscience A/S Fibrosis biomarker assay

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP2438962A3 (en) 2006-02-13 2012-07-18 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US9404932B2 (en) 2007-11-05 2016-08-02 Nordic Bioscience A/S Pathology biomarker assay
EP2538222B1 (en) * 2007-11-05 2021-08-25 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
NZ592432A (en) 2008-11-03 2013-01-25 Alethia Biotherapeutics Inc Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
FI20095733A0 (en) * 2009-06-29 2009-06-29 Hytest Oy Determination of IGFBP-4 fragments as a diagnostic method
JP5899213B2 (en) * 2010-08-06 2016-04-06 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ Pearlcan as a biomarker for renal dysfunction
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
PT3173427T (en) 2011-03-31 2019-09-17 Adc Therapeutics Sa Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
GB201107922D0 (en) * 2011-05-12 2011-06-22 Nordic Bioscience As Biochemical markers for CVD risk assessment
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201111788D0 (en) * 2011-07-11 2011-08-24 Nordic Bioscience As In vitro assessment of cardiovascular events by assay for neo-epitopes
CN106243216B (en) * 2011-11-04 2019-12-20 株式会社日皮 DPP-4 inhibitor
CN102565418A (en) * 2011-12-25 2012-07-11 复旦大学附属中山医院 Early-stage diagnosis marker for aorta disease and application thereof
PT2802351T (en) 2012-01-09 2019-06-27 Adc Therapeutics Sa Agents for treating triple negative breast cancer
US20150065391A1 (en) * 2012-01-30 2015-03-05 Mosaiques Diagnostics And Therapeutics Ag Polypeptide markers for diagnosis and assessment of heart failure
EP3699591A1 (en) * 2012-04-02 2020-08-26 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
US20150160201A1 (en) * 2012-04-19 2015-06-11 The Regents Of The University Of California Compositions and Methods for Detecting Unstable Arteriosclerotic Plaques
IN2014KN02933A (en) 2012-07-19 2015-05-08 Alethia Biotherapeutics Inc
CN105555310B (en) 2013-07-08 2019-07-23 南京传奇生物科技有限公司 A kind of composition and method for improving protein serum half-life
GB201400472D0 (en) 2014-01-13 2014-02-26 Nordic Bioscience As Biochemical Markers for pulmonary and other diseases
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US10478130B2 (en) * 2015-02-13 2019-11-19 Siemens Healthcare Gmbh Plaque vulnerability assessment in medical imaging
EP3386528A1 (en) * 2015-12-10 2018-10-17 Lubrizol Advanced Materials, Inc. Compounds useful in the treatment and/or care of the skin, hair, nails, and/or mucous membranes
FI127416B (en) * 2016-09-29 2018-05-31 Oy Medix Biochemica Ab Procedures for assessing risks associated with cardiovascular disease
CN106442979A (en) * 2016-10-17 2017-02-22 赵军理 Fast quantitative immunity test strip used for detecting four indicators of hepatic fibrosis
GB201802070D0 (en) * 2018-02-08 2018-03-28 Nordic Bioscience As Elastin assay
KR20210118864A (en) * 2019-01-22 2021-10-01 클렘손 유니버서티 리서치 화운데이션 Anti-elastin antibodies and methods of use
WO2023148165A1 (en) * 2022-02-01 2023-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing collagen degradatation associated disease
CN116298282B (en) * 2023-04-21 2025-09-09 新疆维吾尔自治区人民医院 Biomarker ADAMTS8 for detecting acute aortic dissection and application thereof
CN117343132B (en) * 2023-09-25 2024-03-12 山东省农业科学院 An ACE inhibitory peptide derived from salmon skin and its preparation method
CN119684440B (en) * 2025-02-25 2025-07-04 深圳柏垠生物科技有限公司 A recombinant human type III collagen and its preparation method and application

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024835A2 (en) * 1997-10-31 1999-05-20 Bayer Aktiengesellschaft An immunoassay for procollagen-iii-c-terminal propeptide
WO1999061477A2 (en) * 1998-05-28 1999-12-02 Bayer Aktiengesellschaft Monoclonal antibody and assay for detecting piiinp
EP1182213A1 (en) * 2000-06-12 2002-02-27 Wako Pure Chemical Industries, Ltd. Hybrid enzyme and use thereof
WO2002088750A2 (en) * 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
US6703219B1 (en) * 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
WO2005050224A2 (en) * 2003-11-13 2005-06-02 Epitome Biosystems Inc. Small molecule and peptide arrays and uses thereof
WO2005124341A2 (en) * 2004-06-09 2005-12-29 Anderson Forschung Group Llc Stable isotope labeled polypeptide standards for protein quantitation
WO2007050661A2 (en) * 2005-10-26 2007-05-03 Science & Technology Corporation @ Unm C-reactive protein and its use to treat systemic lupus erythematosus and related conditions
US20070099242A1 (en) * 2005-10-31 2007-05-03 Heinecke Jay W Lipoprotein-associated markers for cardiovascular disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010862A (en) * 1987-11-06 2000-01-04 Washington Research Foundation Methods of detecting collagen type III degradation in vivo
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
CA2132859A1 (en) * 1992-04-03 1993-10-14 Michael D. Pierschbacher Decorin fragments and methods of inhibiting cell regulatory factors
DK104093D0 (en) * 1993-09-17 1993-09-17 Osteometer A S PROCEDURE FOR DETERMINING COLLAGEN FRAGMENTS IN BODY LIQUIDS, TEST KITS AND MEANS FOR EXERCISING THE PROCEDURE AND USING THE PROCEDURE FOR DIAGNOSTICING THE DISEASES OF TABLET METAL
EP0829724A1 (en) * 1996-09-17 1998-03-18 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Assay for detecting collagen degradation
US6916903B2 (en) * 1998-06-19 2005-07-12 Washington Research Foundation Collagen type III synthetic peptides for collagen resorption assays
US6642007B1 (en) * 1998-11-02 2003-11-04 Pfizer Inc. Assays for measurement of type II collagen fragments in urine
ES2229805T3 (en) * 1999-06-17 2005-04-16 Washington Research Foundation CARTILAGO RESORTION TESTS.
SE0103754L (en) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptides from apolipoprotein B, use thereof immunization, method of diagnosis or therapeutic treatment of ischemic cardiovascular diseases, and pharmaceutical composition and vaccine containing such peptide
ATE458199T1 (en) * 2001-05-04 2010-03-15 Biosite Inc DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROME AND THEIR USES
GB0112626D0 (en) * 2001-05-23 2001-07-18 Osteometer Biotech As Assay of isomerised and/or optically inverted proteins and protein fragments
WO2003021226A2 (en) * 2001-08-31 2003-03-13 Pharmacia Corporation Peptide biomarker and method of identification
JP2005515407A (en) * 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド Soluble CD40L (CD154) as a prognostic marker for atherosclerosis
CA2480326A1 (en) * 2002-04-12 2003-12-11 Cartela Ab Knockout mice and their use
CN1874792A (en) * 2003-09-03 2006-12-06 布里斯托尔-迈尔斯.斯奎布制药公司 Compounds containing matrix metalloproteinase substrates and methods of their use
US20110045504A1 (en) * 2005-12-22 2011-02-24 Noriaki Kume Prognostic Prediction Method for Acute Coronary Syndrome
US9404932B2 (en) * 2007-11-05 2016-08-02 Nordic Bioscience A/S Pathology biomarker assay
EP2538222B1 (en) 2007-11-05 2021-08-25 Nordic Bioscience A/S Biochemical markers for CVD risk assessment
ES2635494T3 (en) 2009-03-30 2017-10-04 Nordic Bioscience A/S Fibrosis Biomarker Assay
GB201107922D0 (en) * 2011-05-12 2011-06-22 Nordic Bioscience As Biochemical markers for CVD risk assessment
WO2012163768A1 (en) * 2011-05-27 2012-12-06 Nordic Bioscience A/S Detection of diagnostic peptides
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201111788D0 (en) * 2011-07-11 2011-08-24 Nordic Bioscience As In vitro assessment of cardiovascular events by assay for neo-epitopes

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703219B1 (en) * 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
WO1999024835A2 (en) * 1997-10-31 1999-05-20 Bayer Aktiengesellschaft An immunoassay for procollagen-iii-c-terminal propeptide
WO1999061477A2 (en) * 1998-05-28 1999-12-02 Bayer Aktiengesellschaft Monoclonal antibody and assay for detecting piiinp
EP1182213A1 (en) * 2000-06-12 2002-02-27 Wako Pure Chemical Industries, Ltd. Hybrid enzyme and use thereof
WO2002088750A2 (en) * 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2005050224A2 (en) * 2003-11-13 2005-06-02 Epitome Biosystems Inc. Small molecule and peptide arrays and uses thereof
WO2005124341A2 (en) * 2004-06-09 2005-12-29 Anderson Forschung Group Llc Stable isotope labeled polypeptide standards for protein quantitation
WO2007050661A2 (en) * 2005-10-26 2007-05-03 Science & Technology Corporation @ Unm C-reactive protein and its use to treat systemic lupus erythematosus and related conditions
US20070099242A1 (en) * 2005-10-31 2007-05-03 Heinecke Jay W Lipoprotein-associated markers for cardiovascular disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BISOENDIAL ET AL: "C-reactive protein and atherogenesis: From fatty streak to clinical event", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 195, no. 2, 21 July 2007 (2007-07-21), pages e10 - e18, XP022344944, ISSN: 0021-9150 *
LIN Y H ET AL: "The relation of amino-terminal propeptide of type III procollagen and severity of coronary artery disease in patients without myocardial infarction or hibernation", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 39, no. 9, 1 September 2006 (2006-09-01), pages 861 - 866, XP025059081, ISSN: 0009-9120, [retrieved on 20060901] *
MOLLOY K J ET AL: "Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity", CIRCULATION, vol. 110, no. 3, 20 July 2004 (2004-07-20), pages 337 - 343, XP002530330, ISSN: 0009-7322 *
SATTA ET AL: "Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples", JOURNAL OF VASCULAR SURGERY, C.V. MOSBY CO., ST. LOUIS, MO, US, vol. 22, no. 2, 1 August 1995 (1995-08-01), pages 155 - 160, XP005141626, ISSN: 0741-5214 *
YING S-C ET AL: "Localization of sequence-determined neoepitopes and neutrophil digestion fragments of C-reactive protein utilizing monoclonal antibodies and synthetic peptides", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 29, no. 5, 1 May 1992 (1992-05-01), pages 677 - 687, XP023683021, ISSN: 0161-5890, [retrieved on 19920501] *
ZANNAD F ET AL: "Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.", CIRCULATION 28 NOV 2000, vol. 102, no. 22, 28 November 2000 (2000-11-28), pages 2700 - 2706, XP002530331, ISSN: 1524-4539 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206464B2 (en) 2007-11-05 2015-12-08 Nordic Bioscience A/S Fibrosis biomarker assay

Also Published As

Publication number Publication date
WO2009059972A2 (en) 2009-05-14
EP2538222B1 (en) 2021-08-25
EP2538223A8 (en) 2013-02-27
EP2538222A3 (en) 2013-04-24
EP2208073A2 (en) 2010-07-21
EP2538221A2 (en) 2012-12-26
ES2777948T3 (en) 2020-08-06
JP6309669B2 (en) 2018-04-11
EP2538222A8 (en) 2013-02-27
EP2538218A8 (en) 2013-02-27
EP2538223A2 (en) 2012-12-26
EP2538221A3 (en) 2013-04-24
EP2538222A2 (en) 2012-12-26
CN108196072A (en) 2018-06-22
US20100323377A1 (en) 2010-12-23
US20160282362A1 (en) 2016-09-29
CN105510601B (en) 2018-04-10
EP2538218A2 (en) 2012-12-26
US9359633B2 (en) 2016-06-07
JP2011503564A (en) 2011-01-27
JP6039879B2 (en) 2016-12-07
JP2015007638A (en) 2015-01-15
CN105510601A (en) 2016-04-20
CN101918846A (en) 2010-12-15
JP2017181509A (en) 2017-10-05
ES2897492T3 (en) 2022-03-01
DK2208073T3 (en) 2020-03-30
EP2208073B1 (en) 2020-01-15
EP2538223A3 (en) 2013-04-24
US10267809B2 (en) 2019-04-23
DK2538222T3 (en) 2021-11-15
EP2538218A3 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
WO2009059972A3 (en) Biochemical markers for cvd risk assessment
WO2013011056A3 (en) Pathology biomarker assay
WO2010021822A3 (en) Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
EA201071435A1 (en) DETERMINATION OF MARIHUANA CONSUMPTION
WO2007061793A3 (en) Modified cardiolipin and uses therefor
WO2008007242A3 (en) Increased specificity of analyte detection by measurement of bound and unbound labels
WO2009143098A3 (en) Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
WO2006031583A3 (en) Methods and compositions for measuring canine bnp and uses thereof
MX2009013009A (en) High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest.
WO2008070229A3 (en) Detection of pathogenic aggregates of protein in a sample by homologous elisa
WO2007059065A3 (en) Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
WO2007102054A3 (en) Turbidimetric immunoassay for assessing human cystatin c
WO2006076687A3 (en) Elisa assays using prion-specific peptide reagents
WO2006102526A3 (en) Identification of biomarkers by serum protein profiling
GB201107922D0 (en) Biochemical markers for CVD risk assessment
GB201111788D0 (en) In vitro assessment of cardiovascular events by assay for neo-epitopes
WO2004081025A3 (en) Differential megaplex immunoassay
CA2366651A1 (en) A method for detecting megsin protein and use thereof
WO2008057767A3 (en) Reduction of non-specific binding in immunoassays
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
WO2007054714A3 (en) Agglutination assay
WO2006096697A3 (en) Methods for determining the bivalency of protein and antibody therapeutics
AU2004209876B2 (en) Assay for protein isoforms
WO2007089563A3 (en) Rabbit monoclonal antibodies against mouse/human id3 proteins
CA2549066A1 (en) Diagnosing acute coronary syndrome by measuring levels of free papp-a

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880123912.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08847014

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008847014

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12740648

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010532571

Country of ref document: JP